Summit Trail Advisors LLC Invests $1.89 Million in Krystal Biotech, Inc. (NASDAQ:KRYS)

Summit Trail Advisors LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the third quarter, HoldingsChannel reports. The firm bought 10,401 shares of the company’s stock, valued at approximately $1,893,000.

A number of other institutional investors have also recently bought and sold shares of the business. Sei Investments Co. increased its position in Krystal Biotech by 18.9% in the 2nd quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock valued at $7,367,000 after acquiring an additional 6,363 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after acquiring an additional 231,255 shares in the last quarter. Shaker Investments LLC OH bought a new stake in shares of Krystal Biotech during the third quarter worth $532,000. Amalgamated Bank boosted its position in Krystal Biotech by 937.9% during the 2nd quarter. Amalgamated Bank now owns 7,577 shares of the company’s stock worth $1,391,000 after acquiring an additional 6,847 shares during the last quarter. Finally, Everence Capital Management Inc. bought a new position in shares of Krystal Biotech in the 3rd quarter valued at about $557,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Up 4.4 %

Shares of KRYS stock opened at $190.40 on Monday. Krystal Biotech, Inc. has a 12 month low of $99.00 and a 12 month high of $219.34. The stock has a market cap of $5.48 billion, a PE ratio of 107.57 and a beta of 0.82. The company’s fifty day moving average price is $179.54 and its 200-day moving average price is $182.54.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same quarter last year, the company earned ($0.67) EPS. The firm’s revenue for the quarter was up 879.9% on a year-over-year basis. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 14.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on KRYS shares. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Citigroup boosted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Finally, HC Wainwright restated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $202.29.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).